Genmab A/S

- There is no mention of any current or future fundraising through debt or equity in the provided transcript. - The company emphasizes disciplined capital allocation, strong financial performance, and growing operating profits despite strategic investments. - They remain committed to deleveraging, targeting gross leverage below 3x by the end of 2027. - No specific plans or announcements about raising new funds via debt or equity were discussed during the call.

- Genmab is making significant strategic investments to advance late-stage development programs, specifically for petosemtamab and Rina-S. - Investments are also directed toward launch readiness activities to support multiple potential product launches. - The investments remain fully aligned with the company's capital allocation priorities, aiming to translate antibody science into meaningful clinical breakthroughs and sustainable shareholder value. - Despite these strategic investments, Genmab has grown operating profit by 23%, signaling disciplined capital management. - The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 while maintaining balance sheet strength and flexibility. - Infrastructure and teams are being established across key European markets (France, Italy, Spain) to prepare for additional launches. - Overall, investments support long-term value creation and growth, including expanding pipeline and commercial capabilities through 2026 and beyond.

- Genmab expects continued strong revenue growth, with Q1 2026 revenue up 25%, driven by momentum across their portfolio, including EPKINLY and product sales. - They forecast 14% total revenue growth for 2026, supported by expanding portfolio and market opportunities. - Planned investments in late-stage development (petosemtamab, arenas) and launch readiness will continue, supporting multiple potential product launches. - They anticipate sustained revenue growth through disciplined prioritization, operating discipline, and scalability. - The rapid enrollment in Phase III trials (e.g., RAINFALL 02 for Rina-S) is expected to accelerate pivotal data availability and support future product launches. - Focus on growing commercial presence, including in Europe (France, Italy, Spain), to expand market penetration. - Commitment to deleveraging financials while maintaining a strong balance sheet to support long-term growth.

- Genmab expects continued revenue growth in 2026, targeting approximately 14% total revenue increase driven by key products like EPKINLY and their oral portfolio. - Operating expenses are forecasted to be in the range of $2.7 billion to $2.9 billion, reflecting planned investments in late-stage development (e.g., petosemtamab, arenas) and launch readiness. - Despite increased investments, Genmab projects sustained strong operating profitability with a 23% growth in operating profit in Q1 2026, highlighting disciplined execution. - The company aims to maintain substantial profitability in 2026 while investing strategically to support long-term value creation. - Genmab remains committed to deleveraging, targeting gross leverage below 3x by the end of 2027, maintaining a strong and flexible balance sheet. - Overall, the financial guidance indicates ongoing momentum, expanding portfolio strength, and disciplined capital allocation supporting sustainable long-term growth.

The transcript does not provide explicit details on the current or expected orderbook or pending orders. However, relevant insights related to demand and uptake include: - EPKINLY (a bispecific antibody) is experiencing strong demand and commercial performance, driven by physician appreciation for dual indication, efficacy, and subcutaneous administration. - There is enthusiasm and anticipation for the Phase III frontline DLBCL trial results (EPKINLY), which could drive further adoption. - The Peto trial is enrolling extremely well, with no need for additional sites or increases in size impacting timelines. - The company expects one or more key Phase II/III readouts this year that will be significant commercial catalysts. - Uptake in the academic and community settings is growing, supported by convenience and safety profiles. No specific orderbook numbers or pending order details are disclosed in the provided pages.